my (second) last ever post on the plt thread, page-7

Decan,

You said that:
>>>
"Pioneering any new market with a new product/technology takes many years of preparation and many tens of millions of dollars in launch costs. That it PLT's challenge with Truscreen as I see it."
<<<

Disagree. The costs incurred and incurred primarily by the distributors, and you don't understand Polartechnics' business assuming those kinds of costs. The distributors are all large, solid & established distributors of many medical products, not just TruScreen, and in most cases they have been working the pipeline for quite a while now. The initial sales of 260 TruScreen units (mainly to China & India; will be 360 once Pakistan political situation settles down), did not take tens of millions of dollars of PLT's money to market, nor will the next 2000 units sold and shipped. R&D to make TruScreen as good as it is, is another matter, but that's been done & ready for years of tax-free profits from now on!

Getting CerviScreen & STI as big as they like is a different matter of course, but I still don't think its in the order of magnitude you're talking about for financing for Polartechnics; possibly distributors.

...

As for your comment:
>>>>>>>
Why would any major customer in BRIC commit to Truscreen in volume when they know CareHPV is about to launch?"
<<<<<<<

CareHPV is a future product, TruScreen is here & now and already out there in both China and India, and being solidly evaluated elsewhere. It is already providing solid results, and in demand. CareHPV does not appear to offer advantages other than it's good for taking the truck out to the asian version of woop-woop to gather the village people together and get some screening done. Different application, and of no comparative benefit for hospitals.

Cheers.